(Adds details)
BENGALURU, Jan 17 (Reuters) - Indian drugmaker Eris
Lifesciences Ltd ERIS.NS said on Tuesday it would acquire a
portfolio of dermatology brands from Glenmark Pharmaceuticals
Ltd GLEN.NS for 3.4 billion rupees ($41.63 million) to deepen
its presence in the anti-fungal and anti-psoriasis segments.
The deal, through Eris' dermatology focused unit, is for the
purchase of nine brands, including Onabet, Halobate, Sorvate,
and Demelan for India and Nepal, Eris said.
Glenmark said, post divestiture of the brands, it will
further consolidate its position in the core therapeutic areas
of cardiometabolic, respiratory, dermatology, and oncology
segments.
The deal for the portfolio that has an annual revenue base
of 850 million rupees, will be financed through borrowings, and
the transaction is expected to achieve financial closure very
soon, Eris said.
Separately, Eris on Tuesday reported a consolidated net
profit of 1.02 billion rupees in its third quarter, from 1.01
billion rupees a year earlier. urn:newsml:reuters.com:*:nFWN3421CD
($1 = 81.6740 Indian rupees)
(Reporting by Yagnoseni Das in Bengaluru; Editing by Shailesh
Kuber)
((Yagnoseni.Das@thomsonreuters.com; +91 6001289066))